JANUMET XR (sitagliptin and metformin hydrochloride) by Merck & Co. is 2 diabetes mellitus: sitagliptin, a dipeptidyl peptidase-4 (dpp-4) inhibitor, and metformin extended-release, a member of the biguanide class. First approved in 2012.
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
JANUMET XR is a fixed-dose oral combination of sitagliptin (a DPP-4 inhibitor) and extended-release metformin for type 2 diabetes. It works by increasing incretin hormone activity to boost insulin secretion and reduce glucagon, while metformin decreases hepatic glucose production and improves insulin sensitivity. The combination provides complementary mechanisms to lower both basal and postprandial glucose levels.
With LOE approaching in 2027 and $392M in annual Part D spending, the brand team is likely preparing for generic erosion and transitioning to lifecycle management strategies focused on retention and lifecycle extension.
2 diabetes mellitus: sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin extended-release, a member of the biguanide class. Sitagliptin Sitagliptin is a DPP-4 inhibitor, which exerts its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones.…
Worked on JANUMET XR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
$392M Medicare spend — this is a commercially significant brand
JANUMET XR currently supports 838 linked job openings, primarily in R&D, Regulatory Affairs, and Medical Affairs at Merck. Professionals joining the team should expect roles focused on lifecycle management, payer relations, and generic defense rather than innovation or expansion.
838 open roles linked to this drug